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. Extreme thickening of the intima or even plaque rupture with subsequent thrombus formation may seriously hamper coronary blood flow, eventually leading to myocardial infarction [8] . Thus, atherosclerosis is a potential life-threatening condition and understanding the cause of atherosclerosis may contribute to the treatment and possibly prevention of this disease.
Atherosclerotic plaque formation is a dynamic multi-cellular process in which the activity of the different cell types involved is essentially determined by the regulation of different genes [3] [4] [5] [6] [7] [8] . [9] . Here, we review the role of epigenetic regulation in vascular remodelling and in the activity of immune cells involved in atherosclerotic plaque formation. [10] [11] [12] .
Nowadays we are fully aware of the important involvement of epigenetic processes in the regulation of gene expression. Understanding these processes is critical for our understanding of inflammatory responses and disease. For instance, not only is cytokine expression under epigenetic control, cytokines themselves induce (indirect) changes to the chromatin, providing an essential link between inflammation and epigenetic programming

Epigenetics explained
Although all cells in our body contain the same genetic material, each cell acts in a cell-type specific manner, as determined by its gene expression profile. Epigenetic mechanisms control gene expression without modifying the actual genetic code, while the altered gene expression patterns can be passed on to the daughter cells upon cell division or even transgenerationally
In its natural state DNA is packaged into chromatin, a highly organized and dynamic protein-DNA complex which consists of DNA, histones and non-histone proteins [13] . Epigenetic mechanisms alter the accessibility of chromatin by modifying DNA and by modification or rearrangement of nucleosomes, which include post-translational modifications of histones [14] [15] [16] [17] [18] [19] [20] [21] . Since epigenetic alterations can accumulate in time, environmental factors can have profound effects on the cellular repertoire of expressed genes [10] .
. Accessible chromatin allows gene-regulatory proteins (transcription factors) to interact with their cognate binding sites within the regulatory regions of genes, such as proximal promoters and enhancers/ silencers. In this way, global gene activation and local control of gene-specific transcription is exerted by components of the epigenetic machinery. Moreover, environmental factors have an important role in the establishment of the epigenome
Already in 1975 DNA methylation was proposed to play a role in regulating gene transcription [22, 23] . Generally speaking, DNA methylation is associated with low gene activity. Actively transcribed genes are usually maintained in an unmethylated state in their promoter regions [24] [25] [26] . DNA 
methylation involves methylation at the C5 position of cytosine residues in a CpG dinucleotide (i.e. cytosine followed by a guanine) context, exerted by DNA methyltransferases (DNMTs). DNMTs are capable of both methylation and demethylation -as has been postulated in two recent
reports -thus making the modification reversible [27, 28] . Notably, CpG dinucleotides are underrepresented in the genome of eukaryotes, but can be found in clusters -so-called 'CpG islands' -which in turn are mainly found in promoter regions. The term 'CpG island' is defined as a region of at least 500 base pairs with a CG content greater then 55% [29] .
For many years it was thought that functionally relevant DNA methylation occurs at the CpG islands within the promoter region. However, in a recent study by Irizarry et al. it [31, 32] . Modifications of histone tails include (amongst others) acetylation and methylation of lysine residues. Whereas acetylation of histone tails is correlated with gene activation [33] [34] [35] , the influence of histone methylation depends on the exact residue methylated and the number of added methyl groups [36] [37] [38] . Histone modifications and DNA methylation provide a close interplay with respect to gene regulation as both activities are functionally linked [39] .
Whereas lysine methylation and acetylation are the most studied modifications, there are many more histone modifications known. Arginine residues can also be methylated and acetylated, just as lysine residues. As is the case with lysine methylation, whether arginine methylation results in repression or activation of transcription depends on which arginine residue is methylated [40] . In addition, SUMOylation and ubiquitination of histones has also been observed [32] . SUMOylation appears to be associated with transcriptional repression [41] , whereas ubiquitination has been suggested to play a role in transcriptional activation and elongation [42] . However, the exact function of these modifications remains to be elucidated. (Fig. 1) . In this way these enzymes promote a return to, respectively, repressive or active chromatin structure [43] [44] [45] .
Epigenetic alterations are reversible
Importantly, the reversible nature of these epigenetic modifications makes the chromatin-modifying enzymes interesting therapeutic targets [46] [47] [48] [50] [51] [52] . With respect to atherosclerosis, administration of curcumin (a KAT inhibitor) resulted in significantly lowered low-density lipoprotein levels and raised high-density lipoprotein levels in healthy volunteers [53] [54] [55] . It has also been reported that curcumin has an anti-proliferative effect on peripheral blood mononuclear cells (PBMCs) and vSMCs [56] .
Atherosclerosis
The first step in atherosclerosis is thought to be endothelial dysfunction [57] , possibly triggered by oxidized low-density lipoprotein (OxLDL) [5] . Endothelial [5] . Although fatty streaks are not clinically significant, they are thought to be the precursors to more advanced lesions, although there is some dispute whether fatty streaks are truly precursors of advanced lesions [7, 58] [192] . [68, 69] . Different genetic variants of the TNF-␣ gene also showed to be important for the outcome of percutaneous coronary intervention (PCI, one of the treatments used for opening of occluded vessels) with respect to restenosis -one of the major limitations of the PCI technique [66] . Genetic variants of the IL-10 gene have also proven to be important for the development of restenosis [70] .
and TGF-␤) resulted in increased atherosclerosis
The [3, [72] [73] [74] [75] [76] . The importance of DNA methylation as a contributing factor to the pathogenesis of atherosclerosis is underscored by a study linking global DNA hypermethylation with predisposition to, and natural history of atherosclerosis [77] [78] . Furthermore, a positive correlation was found between global DNA methylation and homocysteine levels. Homocysteine is known to be an independent risk factor for CAD [79, 80] . Sharma [103] and in T cells treated with DNMT inhibitors (DNMTi) [104, 105] . In addition, expression of IFN-␥ by NK and NKT cells is also controlled by epigenetic processes [99] . [110, 111] . [114] . Furthermore the 'master-switch' for some typical endothelial expressed genes (HoxA9, which regulates eNOS, VEGF receptor 2 and VE-cadherin expression) was also down-regulated in its expression by KDACi administration [115] . [116] . CArG boxes serve as a binding site for the transcription factor SRF [117] . However, SRF expression is not limited to SMCs and serves many functions in different cell types including cell migration and cell-cell adhesion [118] .
cross-talk between immune system and vascular wall results in up-regulation of major histocompatibility complex (MHC) class II (MHC-II) molecules and of the MHC class Ib molecule, HLA-E [3, 71]. Furthermore, it results in up-regulation of chemokines such as CX3CL1 (fractalkine), CCL2 (MCP-1), CCL5 (RANTES) and their receptors
. All of these factors influence the gene expression profiles of cells present within the lesion. These observations not only feed the current theory that atherosclerosis is an inflammatory disease -and not just a disease of lipid metabolism. For many of these inflammatory and immune modulating factors epigenetic components have been identified that are responsible for the transcriptional regulation of the genes encoding these factors. Thus epigenetic processes might prove to be important contributing factors to disease pathogenesis that should be taken into consideration.
Epigenetics and association with atherosclerosis
Epigenetics provides an attractive explanation how diet, environment and lifestyle may contribute to disease. In principle, epigenetics explains how such external factors can impose aberrant gene expression patterns in an individual lifetime and even transgenerationally. One of the earliest studies linking DNA methylation to atherosclerosis showed that the extracellular superoxide dismutase (ec-SOD) gene was hypomethylated in atherosclerotic lesions in rabbits
Endothelial cells
Epigenetic mechanisms are also directly involved in the transcriptional regulation of immune genes in the vascular wall. For instance, in cultured human ECs it was found that administration of the KDACi TSA inhibited TNF-␣ induced monocyte adhesion. This was the result of down-regulation of the VCAM-1 gene; however, ICAM-1 and E-selectin -two other cytokines inducible genes -were not affected [112]. This suggests that the KDACi modulated TNF-␣-mediated signalling specifically targets the VCAM-1 promoter, instead of general inhibition of the NF-B pathway. This notion is interesting, since NF-B is a target for chromatin modifying enzymes as well (see 'Non-histone targets' below). Similar results have been presented for the induction of tissue factor (TF) in human ECs. The human TF promoter contains a NF-B related binding site: TF-B. KDACi administration inhibited agonist induced (TNF-␣, IL-1␤ or LPS) TF activity in ECs by blocking activation of TF-B (TF activity was reduced 90% in HUVECs; 50% reduced in PBMCs, in vitro). TSA nearly abolishes TF-B binding, without affecting NF-B binding (as determined by electrophoretic mobility shift assays (EMSAs), chromatin immunoprecipitation (ChIP) and luciferase promoter reporter assays). These results were achieved using a variety of structurally distinct KDACi's [113]. Work performed in the group of Stefanie Dimmeler showed an important role for KDACs in regulating several endothelial-specific genes. Using KDACi's, it was shown that eNOS mRNA and protein levels decreased after KDACi administration
Smooth muscle cells
The data reported in literature regarding epigenetic regulation in SMCs provides an explanation how epigenetics may control lineage specificity. Nearly all SMC-restricted protein genes contain the CArG box DNA sequence within their promoter and this sequence is also required for SMC gene transcription in vivo. Genes important for SMC phenotypic switching (e.g. genes important for migration, proliferation and ECM production) also contain CArG boxes within their promoters
Multiple [119, 126] . [134] . A study performed by Mellott et al. showed that cytokine induction of iNOS resulted in a change of chromatin structure at the iNOS promoter [9] . Later 
Chemokines, their receptors and other genes involved in inflammation
Expression of immune response genes in vECs and vSMCs is a major determinant in atherosclerosis onset and development because it contributes to the vascular-immune cross talk. The vascular wall modulates inflammation by the expression of numerous cytokines and chemokines. For many of these genes epigenetic components, influencing expression, have been identified. Below, we will discuss some of the best-studied examples in detail.
eNOS
As stated in the previous sections, many inflammatory processes are recognized by an epigenetic component. One of the best-studied cases of epigenetic regulation in the vascular wall involves the transcription of eNOS, an enzyme which is regarded as endothelial specific. Its catalytic product, nitric oxide, was first identified as a vasodilator [127], although recent evidence also suggest a role in inflammation. Nitric oxide has been attributed roles in leucocyte adhesion and vSMC proliferation [128]. Furthermore, dysfunctional eNOS is believed to be implicated in atherosclerosis development [129]. The human eNOS promoter does not contain a canonical TATA box, nor does it contain a proximal CpG island. Expression of eNOS is restricted to ECs in vivo. Various assays in both expressing and non-expressing cell types showed that a majority of the non-expressing cell types displayed transgene promoter activity [130-132]. In eNOS expressing ECs, eNOS promoter DNA was only slightly methylated or unmethylated, whereas non-expressing cells showed a high amount of DNA methylation. Treatment of non-expressing cell types with 5-azacytidine (a DNMTi) led to an increase in eNOS mRNA levels [132]. Later experiments showed the involvement of histone modifications in the expression of eNOS as well. ChIP showed enrichment of AcH3, AcH4 and (2/3)MeK4H3 in chromatin of the eNOS promoter in eNOS expressing cells. Treatment of non-expressing cells with the KDACi TSA -effectively increasing histone acetylation -also led to an increase in eNOS mRNA [128 and references therein].
iNOS
Not only is eNOS regulated by epigenetic mechanisms, of interest is the observation that also inducible nitric oxide synthase (iNOS) is actively regulated by the epigenetic mechanisms [133]. This gene is expressed in macrophages, but also in ECs and vSMCs, under inflammatory conditions. It has been suggested that nitric oxide -derived from macrophages expressing iNOS -can result in apoptosis of vSMCs, promoting plaque instability
CCL11 (eotaxin)
In human atherosclerotic plaques, the chemokine CCL11 (also know as eotaxin) was shown by immunohistochemistry to be expressed [135] . In healthy tissue only negligible amounts of CCL11 were found. Polymorphisms within the CCL11 gene are also associated with the development of restenosis after PCI [136] . CCL11, an eosinophil chemoattractant, has been suggested to play a role in atherosclerosis development, although the precise relation remains to be elucidated [135, 137, 138] . At the same time CCL11 is expressed by SMCs, while macrophages in the human atherosclerotic plaque express the CCL11 receptor, CCR3 [135] [139] . Notably, glucocorticoids repress CCL11 transcription through selective inhibition of histone H4 acetylation [139] . Although only histone H4 acetylation and no other epigenetic markers were investigated, this research provides a very strong indication for epigenetic regulation of the CCL11 gene [139] . [140, 141] . One of the ligands for the CCR5 receptor, CCL5 or RANTES, has also been shown to be involved in unstable angina pectoris (UAP) [142] [143] . Jmjd3 binds to PcG target genes, regulates 3MeK27H3 levels and therewith their transcriptional activity [145] . For the first time, an inducible enzyme was shown to erase epigenetic modifications. Later work showed that 70% of lipopolysaccharide-inducible genes in macrophages are Jmjd3 targets [146] . This provides an essential link between inflammation and reprogramming of the epigenome and might prove to be of vital importance in chronic inflammation and autoimmune diseases including atherosclerosis in the near future.
. CCL11 transcription is induced by inflammatory TNF-␣ signalling and is mediated through NF-B. TNF-␣ induces acetylation of histone H4 in the CCL11 promoter. This results in an open chromatin structure, promoting subsequent binding of the NF-B subunit p65 to the CCL11 promoter (as shown by ChIP)
CCR5
CCR5 is important for plaque formation as it attracts T cells and mononuclear cells. Ccr5 knockout mice show less neointima formation and an increase in production of the anti-inflammatory IL-10 molecule by SMCs
Oestrogen receptor
Oestrogen receptors (ERs) are present in the coronary arterial wall on both SMCs and ECs [147] [148] [149] . ERs may play an important role in protection against atherosclerosis [148] . Deficiencies in ER-␣ lead to accelerated atherosclerosis in men, furthermore ER-␣ mediates the loss of expression of some cytokine induced cell-adhesion molecules [150 and references therein] . ER ␣ was shown to have a varying degree of methylation throughout the cardiovascular system [151] . In the same study it was shown that an age related increase of methylation occurred in the right atrium. Furthermore, higher degrees of methylation were found in coronary atheromas when compared to macroscopically normal tissues.
Similarly, the ER-␤ also displays a correlation in methylation of its promoter and atherosclerosis [152] . Contrary to ER-␣ expression, expression of ER-␤ correlates with atherosclerosis independent of age [153] . By comparing plaque versus non-plaque tissue from the same vessels, it was recently shown that the ER-␤ promoter has higher methylation levels in atherosclerotic lesions [152] . [156] . Therefore under inflammatory conditions MHC-II molecule expression can be induced on vECs and vSMCs, which normally are not expressing MHC-II [157, 158] .
In this study, increased expression of ER-␤ was also observed -in vitro -in ECs and SMCs after administration of a DNMTi (5-aza-2Ј-deoxycytidine) and a KDACi (TSA
The 'master regulator' of MHC-II expression is the co-activator CIITA (class II transactivator) [159] . Within the context of atherosclerosis, CIITA is of importance, since it has been shown to be involved in transcriptional regulation of collagen type 1 [160, 161] . Collagen 1 is one of the main components of ECM and is essential in cap formation and plaque stabilization [57] .
Transcriptional regulation of MHC2TA, the gene encoding CIITA, is mediated through the activity of four independent promoter units (CIITA-PI through CIITA-PIV, Fig. 3 ) [162] . These promoter units are employed in a cell type-and activation-specific manner. In aortic SMCs CIITA-PIII and -PIV are expressed after IFN-␥ stimulation and CIITA is needed for IFN-␥-mediated repression of collagen type 1 genes (COL1A1 and COL1A2) [160, 161] . Furthermore, collagen transcription is also repressed by the RFX family proteins. RFX1 only weakly interacts with the unmethylated collagen promoter, but binds with higher affinity when the promoter is in a methylated state [161] .
In MHC-II transcription, CIITA exerts its transactivating function through protein-protein interactions with a multi-protein complex, which comprises RFX, CREB/ATF and NFY (Fig. 3B ) [163] [164] [165] . Together with CIITA, this complex acts as an enhanceosome driving transactivation of these genes [163] [164] [165] . In the MHC-enhanceosome, CIITA acts as a platform for recruitment of chromatin-modifying activities which include KATs, KDACs and an arginine methyltransferase [166] [167] [168] . Interactions of these chromatin-modifying enzymes and CIITA result in higherorder structural changes within the chromatin, effectively activating or silencing MHC-II gene transcription [167, 169] . A number of studies now have shown that epigenetic processes not only control MHC-II transcription, but also contribute to the activating/silencing of MHC2TA transcription. This is illustrated by the observation that in DC maturation deacetylation occurs at the MHC2TA locus coinciding with transcriptional inactivation [170] . During DC differentiation histone acetylation of the type I promoter is increased. This increase was blocked by IL-10, inhibiting MHC2TA transcription [171] .
Non-histone targets
Acetyltransferases/deacetylases and methyltransferases/demethylases discussed in the previous sections also target non-histone proteins which could lead to alterations in function of the targeted proteins or the generation of novel epitopes which now can evoke an adaptive (auto-) immune response [172] . Especially since NF-B -playing crucial roles in inflammation -is showing up as one of the non-histone substrates. Both NF-B and p53 are acetylated by KAT3A (CBP) and KAT3B (p300) [173] [174] [175] [176] , whereas p53 can also be acetylated by KAT2B (PCAF) [177, 178] .
As [151] ER-␤ DNA methylation and histone code [152] CIITA DNA methylation and histone code [166] [167] [168] [169] [170] [171] 
MicroRNAs
In recent years it became apparent that microRNAs (miRNAs) are critically involved in the regulation of gene expression. Synthesized as a larger precursor in the nucleus, miRNAs are processed in the cytoplasm into mature miRNAs, where they target specific mRNAs for degradation or translational inhibition [187] . A large number of miRNAs have already been identified at the moment and, not surprisingly, miRNAs have also been found to be involved in inflammation and atherosclerosis [188] . Unfortunately for most miRNAs the target they act upon is yet to be identified.
For some miRNAs, which might play a role in atherosclerosis development or inflammation the miRNA target gene has been identified. For instance the EC specific miR-126 inhibits the (TNF-␣ mediated) expression of VCAM-1 [189, 190] 
